Stockscreener 앱 받기
22.93
1.70%
0.30
전일 마감가:
$22.63
열려 있는:
$22.92
하루 거래량:
531.71K
Relative Volume:
0.23
시가총액:
$2.90B
수익:
$715.22M
순이익/손실:
$-250.10M
주가수익비율:
-11.30
EPS:
-2.03
순현금흐름:
$-205.58M
1주 성능:
+1.12%
1개월 성능:
-16.52%
6개월 성능:
+1.48%
1년 성능:
-17.03%
1일 변동 폭
$22.79
$23.50
1주일 범위
$21.07
$23.50
52주 변동 폭
$16.10
$35.72
아펠리스 Stock (APLS) Company Profile
명칭
Apellis Pharmaceuticals Inc
전화
617-977-5700
주소
100 FIFTH AVENUE, WALTHAM, KY
APLS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
22.95 | 2.86B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
405.89 | 100.41B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.64 | 59.59B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
463.50 | 59.77B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
775.48 | 45.14B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
345.21 | 37.42B | 3.81B | -644.79M | -669.77M | -6.24 |
아펠리스 Stock (APLS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-26 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-05-09 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-05-09 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-17 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-11-21 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-10-25 | 개시 | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-10-16 | 개시 | William Blair | Outperform |
| 2024-05-31 | 개시 | Piper Sandler | Neutral |
| 2024-02-05 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-12-14 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | 개시 | Goldman | Buy |
| 2023-11-02 | 개시 | Mizuho | Neutral |
| 2023-10-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-09-15 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | 재확인 | Citigroup | Buy |
| 2023-08-03 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2023-08-01 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-01-03 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-19 | 개시 | H.C. Wainwright | Buy |
| 2022-06-17 | 재개 | Stifel | Buy |
| 2022-04-14 | 다운그레이드 | ROTH Capital | Neutral → Sell |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-11-29 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2021-09-10 | 재확인 | BMO Capital Markets | Outperform |
| 2021-09-10 | 재확인 | Credit Suisse | Neutral |
| 2021-09-10 | 재확인 | Needham | Buy |
| 2021-09-10 | 재확인 | Oppenheimer | Outperform |
| 2021-09-10 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-08-19 | 개시 | Jefferies | Buy |
| 2021-08-19 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-04-16 | 개시 | Goldman | Buy |
| 2020-11-19 | 개시 | Needham | Buy |
| 2020-09-01 | 개시 | Stifel | Buy |
| 2020-07-20 | 개시 | ROTH Capital | Buy |
| 2020-06-17 | 개시 | BTIG Research | Neutral |
| 2020-04-01 | 개시 | Raymond James | Strong Buy |
| 2020-03-31 | 개시 | BMO Capital Markets | Outperform |
| 2020-03-11 | 업그레이드 | Wedbush | Underperform → Neutral |
| 2020-01-07 | 개시 | SVB Leerink | Mkt Perform |
| 2019-12-19 | 개시 | BofA/Merrill | Buy |
| 2019-11-22 | 개시 | Wedbush | Underperform |
| 2019-11-05 | 개시 | Credit Suisse | Neutral |
| 2019-08-01 | 재확인 | Cantor Fitzgerald | Overweight |
| 2019-07-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-03-29 | 개시 | Robert W. Baird | Outperform |
| 2019-01-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-07-30 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-04-12 | 다운그레이드 | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | 개시 | B. Riley FBR, Inc. | Buy |
모두보기
아펠리스 주식(APLS)의 최신 뉴스
How to monitor Apellis Pharmaceuticals Inc. with trend dashboardsWeekly Investment Summary & Community Consensus Stock Picks - newser.com
Volume spikes in Apellis Pharmaceuticals Inc. stock – what they mean2025 Geopolitical Influence & Risk Controlled Daily Trade Plans - newser.com
Why retail investors pile into Apellis Pharmaceuticals Inc. stockJuly 2025 Opening Moves & Low Risk Investment Opportunities - newser.com
What MACD and RSI say about Apellis Pharmaceuticals Inc.July 2025 PostEarnings & Stepwise Swing Trade Plans - newser.com
What Fibonacci levels say about Apellis Pharmaceuticals Inc. reboundWeekly Stock Recap & AI Driven Price Predictions - newser.com
Apellis Pharmaceuticals: Continued EMPAVELI Expansions Beyond PNH And C3G-Disorders - Seeking Alpha
Wall Street Has a Mixed Opinion on Apellis Pharmaceuticals (APLS) - MSN
What drives Apellis Pharmaceuticals Inc stock priceInstitutional Buying Trends & Free Exceptional Risk Adjusted Gains - earlytimes.in
H.C. Wainwright reiterates Buy rating on Apellis Pharmaceuticals stock By Investing.com - Investing.com Canada
Apellis Pharmaceuticals CFO sells $16,119 in stock - MSN
Published on: 2025-09-29 15:38:29 - newser.com
Can Apellis Pharmaceuticals Inc. stock surprise with earnings upsideQuarterly Profit Review & AI Powered Market Entry Ideas - newser.com
Smart tools for monitoring Apellis Pharmaceuticals Inc.’s price actionWeekly Volume Report & Free Community Consensus Stock Picks - newser.com
Using R and stats models for Apellis Pharmaceuticals Inc. forecasting2025 Winners & Losers & Real-Time Buy Signal Alerts - newser.com
Can Apellis Pharmaceuticals Inc. (1JK) stock sustain institutional flows2025 Historical Comparison & Real-Time Stock Entry Alerts - newser.com
Apellis Pharmaceuticals, Inc. $APLS Shares Acquired by Wealth Enhancement Advisory Services LLC - MarketBeat
Goldman Sachs downgrades Apellis stock to Sell on Syfovre growth concerns By Investing.com - Investing.com Nigeria
12 Analysts Assess Apellis Pharmaceuticals: What You Need To Know - Benzinga
Goldman Sachs Downgrades Apellis Pharmaceuticals (APLS) with Low - GuruFocus
Goldman Sachs Downgrades Apellis Pharmaceuticals (APLS) Amid Com - GuruFocus
Apellis down as Goldman Sachs cuts to sell on risks to outlook - MSN
Apellis Pharmaceuticals (NASDAQ:APLS) Shares Gap Down After Analyst Downgrade - MarketBeat
Apellis stock cut to sell at Goldman Sachs (APLS:NASDAQ) - Seeking Alpha
Apellis Pharmaceuticals (NASDAQ:APLS) Lowered to Sell Rating by The Goldman Sachs Group - MarketBeat
Concentrix Posts Downbeat Earnings, Joins Legacy Education, Kingsoft Cloud And Other Big Stocks Moving Lower In Friday's Pre-Market SessionApellis Pharmaceuticals (NASDAQ:APLS), Concentrix (NASDAQ:CNXC) - Benzinga
Why Top KingWin Shares Are Trading Higher By 87%; Here Are 20 Stocks Moving Premarket - Benzinga
Goldman Sachs Downgrades Apellis Pharmaceuticals to Sell From Neutral, Adjusts PT to $18 From $26 - MarketScreener
Goldman Sachs downgrades Apellis stock to Sell on Syfovre growth concerns - Investing.com
Fierce Biotech Layoff Tracker 2025: IO lays off 50% of employees; Heidelberg reduces headcount by 75% - Fierce Biotech
Apellis Pharmaceuticals Forms Golden Cross, Signaling Potential Bullish Breakout - Markets Mojo
Pallas Capital Advisors LLC Has $949,000 Stock Position in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Director Sells $713,561.40 in Stock - MarketBeat
Zacks Research Has Bullish Estimate for APLS FY2025 Earnings - MarketBeat
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) General Counsel Sells $121,700.00 in Stock - MarketBeat
Setup Watch: Should I invest in ATMV before earningsTreasury Yields & Fast Moving Stock Watchlists - khodrobank.com
Dunlop A. Sinclair sells Apellis (APLS) shares worth $713k - Investing.com
Goldman Sachs Group Inc. Has $6.73 Million Stake in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharma director Dunlop sells $713,561 in shares By Investing.com - Investing.com Canada
Apellis Pharma director Dunlop sells $713,561 in shares - Investing.com India
Dunlop A. Sinclair sells Apellis (APLS) shares worth $713k By Investing.com - Investing.com South Africa
Can volume confirm reversal in Apellis Pharmaceuticals Inc.Forecast Cut & Daily Technical Forecast Reports - newser.com
아펠리스 (APLS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.01%
자본화:
|
볼륨(24시간):